Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 3/20 | 0.55 |
| ▸ | TYR | P14679 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL547437 | 1.00 | MIF (0.64) | MIFESR1TYRCA1CA2 | |
| SCHEMBL10021706 | 0.87 | CAPN1 (0.50) | MIFTYRNFKB1CHRNA7APP | |
| SCHEMBL18517696 | 0.85 | MAPT (0.50) | MIFTYRCHRNA7APPBACE1 | |
| SCHEMBL584566 | 0.83 | CYP1A1 (0.55) | MIFESR1CA1CA2CA4 | |
| SCHEMBL30278658 | 0.83 | CYP1A1 (0.55) | MIFESR1CA1CA2CA4 | |
| SCHEMBL584565 | 0.83 | CYP1A1 (0.55) | MIFESR1CA1CA2CA4 | |
| SCHEMBL27882901 | 0.82 | TYR (0.72) | TYRPKMNFKB1CHRNA7ALDH1A1 | |
| SCHEMBL28116621 | 0.82 | TYR (0.72) | TYRPKMNFKB1CHRNA7ALDH1A1 | |
| SCHEMBL28391865 | 0.81 | MIF (0.68) | MIFESR1TYRCA1CA2 | |
| SCHEMBL471946 | 0.81 | MIF (0.68) | MIFESR1TYRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025081932-A1 | RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳市护家科技有限公司 | 2025-04-24 | — | — | WO | claimed |
| CN-119841755-A | Retinol derivative or its salt, and preparation method and application thereof | 深圳市护家科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| EP-3191839-B1 | METHODS FOR INHIBITING HMGB1 ACTIVATION OF MELANOCYTES, METHOD FOR IDENTIFICATION OF AGENTS SUITABLE FOR SUCH INHIBITON | PROCTER & GAMBLE (US) | 2019-07-24 | — | — | EP | claimed |
| EP-3191839-A1 | METHODS FOR INHIBITING HMGB1 ACTIVATION OF MELANOCYTES, METHOD FOR IDENTIFICATION OF AGENTS SUITABLE FOR SUCH INHIBITON | The Procter and Gamble Company (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040242-A1 | METHODS FOR INHIBITING HMGB1 ACTIVATION OF MELANOCYTES, METHOD FOR IDENTIFICATION OF AGENTS SUITABLE FOR SUCH INHIBITON | THE PROCTER & GAMBLE COMPANY (US) | 2016-03-17 | — | — | WO | claimed |
| US-20160077082-A1 | COMPOSITIONS AND METHODS FOR INHIBITING HMGB1 ACTIVATION OF MELANOCYTES | THE PROCTER & GAMBLE COMPANY | 2016-03-17 | — | — | US | claimed |
| EP-0980203-B1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 2007-04-04 | — | — | EP | claimed |
| EP-0980203-A4 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-06-05 | — | — | US | claimed |
| EP-0980203-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | Squires, Meryl (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998042188-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 1998-10-01 | — | — | WO | claimed |
| EP-0003461-B1 | AMINOALCOHOL DERIVATIVES OF ORTHO-HYDROXY-METHYL CINNAMATE, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1981-04-29 | — | — | EP | claimed |
| WO-2025081932-A1 | RETINOL DERIVATIVE OR SALT THEREOF, AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳市护家科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119841755-A | Retinol derivative or its salt, and preparation method and application thereof | 深圳市护家科技有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-111602087-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal element, polymer and compound | JSR株式会社 | 2023-03-24 | — | — | CN | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| US-4210577-A | Stabilizers for synthetic polymers comprising 2,2,6,6-tetramethyl-4-piperidyl carboxylic acid ester, phosphonic acid ester and phenol | ARGUS CHEMICAL CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209431-A | OXIDATION AND HEAT RESISTANCE | WITCO CHEMICAL CORPORATION (US) | 1980-06-24 | — | — | US | disclosed |
| US-4080364-A | Stabilization of polyolefins against degradative deterioration as a result of exposure to light and air at elevated temperatures | ARGUS CHEMICAL CORPORATION (US) | 1978-03-21 | — | — | US | disclosed |
| US-3997551-A | OXIDATION RESISTANCE, STABILIZE POLYMERS | ARGUS CHEMICAL CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | CD14, CD59, SLC19A1 | MIF 16/4885ESR1 2967/4885TYR 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.